Omega Funds goes back to the well with newest $650M fund, taking a 'stage-agnostic' approach to biotech VC
Amid a very difficult back half of the year for biotech investing, some bullish investors are making the case for a major rally in the coming year as pharma looks to utilize its growing mountain of cash. Now, biotech blue-chipper Omega Funds is getting itself set at the starting line.
Omega has closed a $650 million investment fund it’s calling Omega Fund VII, the VC firm’s latest and largest round in its 17 years in existence, it said Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.